EmjardTM M
Empagliflozin and Metformin Hydrochloride
SGLT2 Inhibitor’s combination (Antidiabetic Preparations)
Indication:
EmjardTM M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Dosage & Administration:
Initial Dose: Empagliflozin 10 mg/day and Metformin Hydrochloride 1000 mg/day after meal.
If Glycemic Target not achieved: Empagliflozin 25 mg/day and Metformin Hydrochloride 1000 mg/day after meal.
Maximum dose: Empagliflozin 25 mg/day and Metformin Hydrochloride 2000 mg/day after meal.
This combination should be taken with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to Metformin. Do not initiate or continue if creatinine levels > 1.5 mg/dL (males), > 1.4 mg/dL (females), or if eGFR is below 45 mL/min/1.73 m2.
Preparation:
EmjardTM M 5/500 Tablet: Each box contains 30 tablets in blister pack.
EmjardTM M 12.5/500 Tablet: Each box contains 18 tablets in blister pack.
